GlaxoSmithKline launched a voluntary recall of more than 593,000 asthma inhalers over a defect that could prevent them from releasing accurate medication doses, reports Reuters.
Here are five things to know.
1. The recall involves three production lots of the Ventolin HFA 200D inhalers produced at GSK's manufacturing plant in Zebulon, N.C., according to the report.
2. GSK on Tuesday said it received increased complaints about the device's wrapper bulging, which indicates a leak of the propellant used to deliver the asthma drug through the inhaler, according to the report.
3. The recall only affects products in the U.S., and does not pose a threat to patient safety, GSK spokesman Juan Carlos Molina told Reuters. He said patients are not being asked to return inhalers they've already purchased.
4. GSK said it is working to identify the cause of the defect and will take corrective action, as necessary, according to the report.
5. The manufacturing plant in Zebulon is still producing inhalers.
"We currently don't anticipate a supply impact to Ventolin HFA 200D inhaler as a result of this issue," Mr. Molina said.
More articles on supply chain:
4 thoughts on women in supply chain leadership from DSC Logistics' CEO
11 drugs on FDA's new safety alert list
EpiPen consumers launch class-action lawsuit against Mylan over price hikes